In 2017, Invitae Corporation (NVTA) was growing at a rapid clip. But it was burning through cash at ...
Eli Lilly: Solid as a Rock
11/13/2017 5:00 am EST
Eli Lilly and Company (LLY) was founded in 1876 and is headquartered in Indianapolis; If you want solidity and stability in your investments, you can get it here, notes Todd Shaver, editor of BullMarket.com.
The company is worth $87 billion, pays a 2.5% dividend and has moved from $20 in 2008 to its current level, in a pretty straight line.
Revenues are solid too. Revenues had a nice bump from the $20 billion in 2015 to the 2016 total of $21.2 billion. This year looks like $23 billion is in the bag. Slow and steady.
And profitable. $2.7 billion ($3.00 a share) to the bottom line after taxes in 2016 up from $2.4 billion in 2015. Not counting some non-recurring charges this year, the company should hit north of $4 billion before tax and about the same as last year in 2017. Solid.
The company offers products to treat diabetes; osteoporosis; human growth hormone deficiency; and testosterone deficiency.
It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and adult brain imaging.
In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and migraine headaches.
And this is just a small part of what they do for humans. They do similar things for animals and are noted for their science and expertise. This is truly a worldwide leader in big pharma.
This amazing company should hit another $3 a share in 2017, giving the firm a PE of under 28. We expect the company to hit the $4 level in a few years and wouldn’t be surprised to see the stock in the 90s within two years. I my view, this stock is as solid as a rock.
Related Articles on HEALTHCARE
A full-scale recession is unlikely at this point, so we remain fully invested in high dividend stock...
John Reese, editor of Validea, selects stocks for his model portfolio based on the investing strateg...
ICON (ICON) — a clinical-research organization (CRO) — helps biotechnology and pharmaceu...